NCT06838546View on ClinicalTrials.gov

A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

January 31, 2027

Conditions
Advanced Colorectal Cancer
Interventions
DRUG

B1962

B1962 has higher VEGF anti angiogenic activity than its competitors. Phase I clinical trials have shown that B1962 has excellent safety and promising therapeutic effects. Large scale clinical studies may achieve better therapeutic effects than similar competitors targeting the same target

Trial Locations (1)

310009

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hanzhou

All Listed Sponsors
collaborator

Sir Run Run Shaw Hospital

OTHER

lead

Tasly Biopharmaceuticals Co., Ltd.

INDUSTRY